Brent Norton, M.D. is the new executive chairman of the board and acting chief executive officer at Ortho Regenerative Technologies Inc. According to the October 18, 2016 news release, Dr. Norton succeeds Edward Margerrison who will be leaving the corporation to assume an executive position with a federal agency.
“On behalf of the Board, I would like to thank Ed for leading Ortho RTI from an early stage, research-focused company through to the stage where the first-in-human clinical trial is within sight and the product profile has been well defined, ” said Steve Saviuk, chairman of the Board. “I am delighted that Brent continues his commitment to the corporation by assuming the executive leadership. His extensive experience with leading development stage companies to significant value-creating milestones, combined with his previous experience in sports medicine, makes him an ideal professional to lead Ortho through the first-in-human studies for its product.”
“Brent Norton is a leader in the life science industry with executive and board experience in several successful companies that achieved significant multiples for investors. Dr. Norton has been involved in IPOs [initial public offerings] and listings on both the TSX [Toronto Stock Exchange] and AMEX [American Stock Exchange] exchanges, has built R&D and commercial operations, led transactions with AstraZeneca, Eli Lilly, L’Oreal and others, and has taken products through FDA approval to global out-licensing with Johnson & Johnson. He is a founding Director of Novadaq Technologies (TSX:NDQ, NASDAQ:NVDQ), one of Canada’s most valuable medical device companies. He is currently a Venture Partner at Lumira Capital, a venture capital fund manager investing in life sciences and biotech companies in North America. Dr. Norton has been an active member of several boards, public and private, in both Canada and the US. He is also an Advisory board member for the Ivey International Centre for Health Innovation and Director of Alpine Ontario. Dr. Norton earned his MD at McGill University, and his MBA at the Richard Ivey School of Business.”
Dr. Norton told OTW, “I am looking forward to moving the product though to its first human testing in 2017 and putting the longer term financial resources in place to grow the company. I’m most enthused about taking a product with newly issued U.S. patents towards a market that is safe, fills a massive unmet medical need and ensuring it is easy to access.”
